Argus Research analyst John Staszak downgrades Sysco (NYSE:SYY) from Buy to Hold.
Goldman Sachs Initiates Coverage On PTC Therapeutics with Sell Rating, Announces Price Target of $35
Goldman Sachs analyst Paul Choi initiates coverage on PTC Therapeutics (NASDAQ:PTCT) with a Sell rating and announces Price Target of $35.